All In Biotech

Drug Trial Radar · NCT07938164

ACUTE-GO is a Study Testing the Effectiveness and Safety of Two Doses of Purified Cortrophin Gel in Patients With Acute Gouty Arthritis Flares

A Randomized, Multi-Center, Double-blind, Efficacy and Safety Study of Two Dose Levels of Purified Cortrophin® Gel in Patients With Acute Gouty Arthritis Flares

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Jan 28, 2026

Primary completion

Nov 30, 2027

Study completion Nov 30, 2027

Sponsor

Lead sponsor
ANI PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if Purified Cortrophin Gel can help people with acute gouty arthritis when they are having a sudden flare-up. It will also monitor participants for any potential side effects while on this therapy. The main question it aims to answer is: is there a change in gout pain intensity after receiving Purified Cortrophin Gel. Researchers will compare two different doses of Purified Cortrophin Gel. Participants will: * Receive one injection of Purified Cortrophin Gel * Have 2 in-person visits to the site and 3 virtual/telephone visits * Complete daily surveys about their gout flare

Conditions

  • Acute Gouty Arthritis

Interventions

  • Purified Cortophin Gel, 40 UDrug

    One injection of Purified Cortrophin Gel, 40 U

  • Purified Cortophin Gel 80 UDrug

    One injection of Purified Cortrophin Gel, 80 U

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in gout pain intensity from baseline in the target joint following PCG administration.Time frame: From baseline to Day 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mass General Hospital

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.